

# WITH OCREVUS, YOU HAVE OPTIONS FOR MS.

OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) are 2-times a year\* prescription medicines for adults with relapsing or primary progressive forms of MULTIPLE SCLEROSIS

If you or someone you care about has Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS), we invite you to a free educational event.

Learn more about treating Relapsing MS (RMS) and Primary Progressive MS (PPMS) from an MS expert.

**Discover** why OCREVUS or OCREVUS ZUNOVO may be the right choice for treating Relapsing MS (RMS) and Primary Progressive MS (PPMS)

**Hear** an inspiring story from a person living with Relapsing Multiple Sclerosis (RMS)/Primary Progressive Multiple Sclerosis (PPMS)

**Connect** with others whose lives are affected by Relapsing Multiple Sclerosis (RMS)/Primary Progressive Multiple Sclerosis (PPMS)

### **PRESENTED BY**



Angela M Applebee, MD
Director Of St. Peters Multiple Sclerosis Center



Franchesca
Person living with Relapsing Multiple Sclerosis (RMS)/ Primary
Progressive Multiple Sclerosis (PPMS)

#### WHERE

Zucchinis 1331 North St Pittsfield, MA 01201

### **DATE & TIME**

Tuesday, June 24, 2025 6:00 pm ET Please plan to arrive 30 minutes before the presentation time.

## ---

### SIGN UP FOR THIS PROGRAM NOW!

To register, learn more, or find other events:



1-844-OCREVUS (1-844-627-3887)



www.ocrevus.com/events

Space is limited and advance registration is strongly recommended. Once registered, you will be emailed a link to join the program.

### What are OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO are prescription medicines used to treat:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

It is not known if OCREVUS and OCREVUS ZUNOVO are safe and effective in children.

### Who should not receive OCREVUS or OCREVUS ZUNOVO?

Do not receive OCREVUS or OCREVUS ZUNOVO if you:

- · have an active hepatitis B virus (HBV) infection.
- have had a life-threatening administration reaction to ocrelizumab.
- have had a life-threatening allergic reaction to ocrelizumab,
   hyaluronidase, or any of the ingredients of OCREVUS ZUNOVO. Tell
   your healthcare provider if you have had an allergic reaction to
   OCREVUS or OCREVUS ZUNOVO or any of their ingredients in the past.

For additional safety information, please see the accompanying full Prescribing Information and Medication Guide for OCREVUS.

For additional safety information, please see the accompanying full Prescribing Information and Medication Guide for OCREVUS ZUNOVO.



## INDICATIONS AND IMPORTANT SAFETY INFORMATION (CONT.)

What is the most important information I should know about OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO can cause serious side effects, including:

- Infusion reactions (OCREVUS): Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
- Injection reactions (OCREVUS ZUNOVO): Injection reactions
  are a common side effect of OCREVUS ZUNOVO, which can be
  serious and may require you to be hospitalized. You will be
  monitored for signs and symptoms of an injection reaction
  when you receive OCREVUS ZUNOVO. This will happen during all
  injections for at least 1 hour after your first injection, and for at
  least 15 minutes after all injections following the first injection.
- · Infection:
- Infections are a common side effect. OCREVUS and OCREVUS
   ZUNOVO increase your risk of getting upper respiratory tract
   infections, lower respiratory tract infections, skin infections, and
   herpes infections. Serious infections can happen with OCREVUS
   and OCREVUS ZUNOVO, which can be life-threatening or cause
   death. Tell your healthcare provider right away if you have an
   infection. Your healthcare provider should delay your treatment
   with OCREVUS or OCREVUS ZUNOVO until your infection is gone.
  - Hepatitis B virus (HBV) reactivation: If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS or OCREVUS ZUNOVO. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death.
  - Vaccinations: Tell your doctor about any recent or upcoming vaccinations.
    - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.
    - When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with OCREVUS or OCREVUS ZUNOVO.

- Weakened immune system: OCREVUS or OCREVUS
   ZUNOVO taken before or after other medicines that
   weaken the immune system could increase your risk of
   getting infections.
- Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability and has been reported with ocrelizumab. Symptoms of PML get worse over days to weeks.
- Decreased immunoglobulins: OCREVUS and OCREVUS
   ZUNOVO may cause a decrease in some types of
   immunoglobulins. Your healthcare provider will do blood
   tests to check your blood immunoglobulin levels.

What are the possible side effects of OCREVUS and OCREVUS ZUNOVO?

OCREVUS and OCREVUS ZUNOVO may cause serious side effects, including:

- Risk of cancers (malignancies) including breast cancer:
   Follow your healthcare provider's instructions about standard screening guidelines for breast cancer.
- Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as diarrhea, blood in stool, and stomach pain.
- The most common side effects of OCREVUS ZUNOVO include: injection reactions, respiratory tract infections, and skin infections.

These are not all the possible side effects of OCREVUS and OCREVUS ZUNOVO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

For more information, go to www.OCREVUS.com or call 1-844-627-3887.

For additional safety information, please see the accompanying full Prescribing Information and Medication Guide for OCREVUS.

For additional safety information, please see the accompanying full Prescribing Information and Medication Guide for OCREVUS ZUNOVO.



